Weebit Nano Limited (WBTNF) licenses its embedded memory technology to semiconductor companies, avoiding the costs of manufacturing. Its revenue depends on royalties triggered by production launches from licensees, making these launches crucial for income growth. The company currently has enough funding to support near-term commercialization efforts. This makes WBTNF a speculative buy for investors optimistic about its shift from licensing fees to recurring royalties.
Weebit Nano stock context includes a notably high sell pressure on NOW (ServiceNow Inc) with 93% of Pluang orders selling as of Oct 29, 2026 19:13 WIB. For readers following Technology-sector US stocks on Pluang, here is the market snapshot: out of 150 priced stocks, 21 rose and 127 fell today. Key movers include NOW at USD 122.80 with a -18.20% change, MRVL (Marvell Technology Inc) at USD 221.88 down -11.83%, and CTSH (Cognizant Technology Solutions Corp) at USD 59.00 down -11.09%.
The inaugural SportsTech Breakthrough Awards recognized leading companies and technologies advancing sports technology globally. Winners span categories like athlete performance, wearables, AI analytics, fan engagement, and smart stadium solutions, h...
The global Industrial Control System (ICS) Security Market is projected to grow from $17.91 billion in 2026 to $38.48 billion by 2031, at a CAGR of 16.5%. This growth is driven by rising cyberattacks targeting critical infrastructure and the increasi...
AdvantageLumber.com has introduced Sketch-A-Deck, a free online software that simplifies deck design for homeowners and contractors. The tool allows users to draw custom deck layouts, attach them to their homes, and generate build-ready plans with de...
Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...
Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...
